ClinicalTrials.gg
CompletedNCT02576938Updated Jun 17, 2020Results posted

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of Baricitinib and Placebo in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing baricitinib in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. baricitinib · Dermatitis, Atopic.

Enrollment
9th of 11
124 · median 440
Started
2016
the only one that year
Phase 2
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
9 of 11
Eli Lilly and Company

Among the 11 studies testing baricitinib in Dermatitis, Atopic, this one is the 9th largest by enrollment, is the only one that started in 2016, is the only one in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 11 studies testing baricitinib in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing baricitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have moderate-to-severe Atopic Dermatitis (AD), as determined by all of the following:

    1. EASI of 12 or more
    2. Greater than or equal to 10% of body surface area involvement
    3. Diagnosed with AD at least 2 years prior
  • Have a history of inadequate clinical response to other eczema treatments

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or nursing
  • Participants who do not agree to use adequate
  • Are currently experiencing or have a history of:

    • Skin conditions such as psoriasis or lupus erythematosus
    • Skin disease that requires frequent hospitalizations or intravenous treatment
    • Compromised immunity
  • Serious illness that could interfere with study participation, or a deviation in physical examination, vital sign measurements, , or abnormalities on laboratory tests
  • Currently experiencing or have a history of:

    • Active or latent Tuberculosis or specific immunity disorders and infections
    • or lymphoproliferative diseases in the last 5 years (or cervical, basal or squamous skin cancer re-occurrence in the last 3 years)
    • (HIV)
    • , , or chronic liver disease
  • Have received certain types of vaccinations
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Baricitinib

    Administered once daily in multiple oral dose cohorts for 16 weeks (Triamcinolone 0.1% topical also permitted)

    Drug: Baricitinib · Drug: Triamcinolone (Optional)

  • Placebo comparator
    Placebo

    Administered orally once daily, for 16 weeks (Triamcinolone 0.1% topical also permitted)

    Drug: Placebo · Drug: Triamcinolone (Optional)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50)

    The EASI 50, defined as ≥ 50% reduction from baseline in EASI score, assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe.

    Time frame: Week 16

Secondary outcomes

  1. Change From Baseline in the EASI at Week 16

    The Eczema Area and Severity Index (EASI) assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe. Change from baseline were analyzed with a Mixed-effect Model Repeated Measure (MMRM) with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.

    Time frame: Baseline, Week 16

  2. Percentage Change From Baseline in the EASI at Week 16

    The Eczema Area and Severity Index (EASI) assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.

    Time frame: Baseline, Week 16

  3. Change From Baseline in the Scoring Atopic Dermatitis (SCORAD) at Week 16

    The SCORAD index uses the rule of nines to assess disease extent and evaluates five clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss with Visual Analogue Scales (VAS) where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness). These three aspects: extent of disease (A: 0-102), disease severity (B: 0-18) and subjective symptoms (C:0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103 where 0 = no disease and 103 = severe disease. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.

    Time frame: Baseline, Week 16

  4. Change From Baseline in the Investigator's Global Assessment (IGA) at Week 16

    The IGA consists of a 6-point severity scale to measure characteristics of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall severity assessment. The scale ranges from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease).

    Time frame: Baseline, Week 16

  5. Change From Baseline in the Dermatologic Life Quality Index (DLQI) at Week 16

    The DLQI is a simple, participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). Changes from baseline in DLQI score were analyzed with an MMRM with fixed effects for treatment, time, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit were included as covariates.

    Time frame: Baseline, Week 16

  6. Change From Baseline in the Itch Numerical Rating Scale (NRS) at Week 16

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, time, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit were included as covariates.

    Time frame: Baseline, Week 16

  7. Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Baricitinib

    Pharmacokinetics (PK): Maximum serum concentration (Cmax) of Baricitinib

    Time frame: Week (Wk) 0: Predose, 15-30 minutes (min) postdose; Wk 4: 1.5 - 4 hour (hr) postdose; Wk 8: 4 - 8 hr postdose; Wk 12: Predose; Wk 16: 30 - 90 min postdose.

07

Results

Posted Mar 14, 2018

Participant flow

Participant flow — Overall Study
MilestonePlacebo2 mg Baricitinib4 mg Baricitinib
Started493738
Received at least one dose of study drug493738
Completed292526
Not completed201212
Withdrew: Adverse event536
Withdrew: Protocol violation111
Withdrew: Withdrawal by subject324
Withdrew: Lack of efficacy940
Withdrew: Lost to follow-up201
Withdrew: Physician decision010
Withdrew: Met exclusion criteria010

Outcome measures

PrimaryPercentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50)

The EASI 50, defined as ≥ 50% reduction from baseline in EASI score, assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50)
percentage of participantsPlacebo2 mg Baricitinib4mg Baricitinib
Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50)375761
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Chi-squared · p = =0.065
  • Placebo vs 4mg Baricitinib · Chi-squared · p = =0.027
SecondaryChange From Baseline in the EASI at Week 16

The Eczema Area and Severity Index (EASI) assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe. Change from baseline were analyzed with a Mixed-effect Model Repeated Measure (MMRM) with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the EASI at Week 16
units on a scalePlacebo2 mg Baricitinib4mg Baricitinib
Change From Baseline in the EASI at Week 16-10.84 ± 1.62-16.44 ± 1.72-16.04 ± 1.72
SecondaryPercentage Change From Baseline in the EASI at Week 16

The Eczema Area and Severity Index (EASI) assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Percentage Change From Baseline in the EASI at Week 16
units on a scalePlacebo2 mg Baricitinib4mg Baricitinib
Percentage Change From Baseline in the EASI at Week 16-45.87 ± 5.85-64.19 ± 6.20-64.69 ± 6.21
SecondaryChange From Baseline in the Scoring Atopic Dermatitis (SCORAD) at Week 16

The SCORAD index uses the rule of nines to assess disease extent and evaluates five clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss with Visual Analogue Scales (VAS) where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness). These three aspects: extent of disease (A: 0-102), disease severity (B: 0-18) and subjective symptoms (C:0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103 where 0 = no disease and 103 = severe disease. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Scoring Atopic Dermatitis (SCORAD) at Week 16
units on a scalePlacebo2 mg Baricitinib4mg Baricitinib
Change From Baseline in the Scoring Atopic Dermatitis (SCORAD) at Week 16-11.89 ± 2.88-23.87 ± 3.03-26.54 ± 2.97
SecondaryChange From Baseline in the Investigator's Global Assessment (IGA) at Week 16

The IGA consists of a 6-point severity scale to measure characteristics of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall severity assessment. The scale ranges from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease).

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Change From Baseline in the Investigator's Global Assessment (IGA) at Week 16
units on a scalePlacebo2 mg Baricitinib4mg Baricitinib
Change From Baseline in the Investigator's Global Assessment (IGA) at Week 16-0.9 ± 0.69-1.4 ± 1.31-1.3 ± 1.01
SecondaryChange From Baseline in the Dermatologic Life Quality Index (DLQI) at Week 16

The DLQI is a simple, participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). Changes from baseline in DLQI score were analyzed with an MMRM with fixed effects for treatment, time, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit were included as covariates.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Dermatologic Life Quality Index (DLQI) at Week 16
units on a scalePlacebo2 mg Baricitinib4mg Baricitinib
Change From Baseline in the Dermatologic Life Quality Index (DLQI) at Week 16-6.27 ± 0.82-6.89 ± 0.89-7.96 ± 0.86
SecondaryChange From Baseline in the Itch Numerical Rating Scale (NRS) at Week 16

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, time, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit were included as covariates.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Itch Numerical Rating Scale (NRS) at Week 16
units on a scalePlacebo2 mg Baricitinib4mg Baricitinib
Change From Baseline in the Itch Numerical Rating Scale (NRS) at Week 16-1.72 ± 0.44-2.61 ± 0.47-2.22 ± 0.46
SecondaryPharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Baricitinib

Pharmacokinetics (PK): Maximum serum concentration (Cmax) of Baricitinib

Time frame:
Week (Wk) 0: Predose, 15-30 minutes (min) postdose; Wk 4: 1.5 - 4 hour (hr) postdose; Wk 8: 4 - 8 hr postdose; Wk 12: Predose; Wk 16: 30 - 90 min postdose.
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Baricitinib
nanogram per milliliter (ng/mL)2 mg Baricitinib4mg Baricitinib
Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Baricitinib18.5 ± 70.037.7 ± 38.9

Adverse events

Collected over Baseline to end of study (up to 5 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/49 (0%)0/49 (0%)14/49 (28.6%)
2 mg Baricitinib0/37 (0%)2/37 (5.4%)13/37 (35.1%)
4mg Baricitinib0/38 (0%)1/38 (2.6%)19/38 (50%)
Most frequent serious events
Most frequent serious events
EventPlacebo2 mg Baricitinib4mg Baricitinib
BronchitisInfections and infestations0/491/370/38
CellulitisInfections and infestations0/491/370/38
Staphylococcal infectionInfections and infestations0/491/370/38
EczemaSkin and subcutaneous tissue disorders0/491/370/38
Large intestine polypGastrointestinal disorders0/490/371/38
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo2 mg Baricitinib4mg Baricitinib
Blood creatine phosphokinase increasedInvestigations1/491/375/38
HeadacheNervous system disorders0/492/375/38
NasopharyngitisInfections and infestations2/491/374/38
Dermatitis atopicSkin and subcutaneous tissue disorders5/493/372/38
LymphopeniaBlood and lymphatic system disorders3/490/371/38
CellulitisInfections and infestations3/491/370/38
Gastrooesophageal reflux diseaseGastrointestinal disorders0/492/370/38
NauseaGastrointestinal disorders0/492/370/38
Staphylococcal infectionInfections and infestations0/492/370/38
Subcutaneous abscessInfections and infestations1/490/372/38

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo2 mg Baricitinib4mg BaricitinibTotal
Mean37.3 ± 13.4940.0 ± 14.3836.4 ± 14.4737.8 ± 14.03
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2 mg Baricitinib4mg BaricitinibTotal
Female25151656
Male24222268
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo2 mg Baricitinib4mg BaricitinibTotal
Hispanic or Latino44614
Not Hispanic or Latino453332110
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo2 mg Baricitinib4mg BaricitinibTotal
American Indian or Alaska Native0000
Asian168933
Native Hawaiian or Other Pacific Islander1023
Black or African American79925
White23201861
More than one race2002
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Placebo2 mg Baricitinib4mg BaricitinibTotal
United States423132105
Japan86620
Median EASI Total Score
Median EASI Total Score(units on a scale)Placebo2 mg Baricitinib4mg BaricitinibTotal
Median22.1 (12.0 to 70.3)22.1 (12.2 to 72.0)19.5 (12.2 to 71.4)21.2 (12.0 to 72.0)
08

Study locations

13 sites
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Forward Clinical Trials, Inc
    Tampa, Florida 33624, United States
  • Medical Dermatology Specialists
    Atlanta, Georgia 30342, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Icahn School of Medicine
    New York, New York 10029, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Center for Clinical Studies
    Houston, Texas 77065, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka-shi, 815-0082, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sapporo, 060-0063, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Takaoka-shi, 933-0871, Japan
09

References and documents

Publications

  • Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. Dermatol Ther (Heidelb). 2022 Dec;12(12):2765-2779. doi: 10.1007/s13555-022-00828-5. Epub 2022 Oct 18. PubMed 36255569 ↗
  • King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7. PubMed 33826132 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Feb 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2015
First posted
Oct 15, 2015
Start
Feb 2016
Primary completionActual
Feb 2017
CompletionActual
Mar 2017
Results first posted
Mar 14, 2018
Last update
Jun 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02576938
Responsible party
Sponsor
First posted
Oct 15, 2015
Start date
Feb 2016
Primary completion
Feb 2017
Completion
Mar 2017
Results posted
Mar 14, 2018
Last update
Jun 17, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion